1998 Conference Publication Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trialBrener, SJ, Barr, LA, Cohen, ED, White, HJ, Moliterno, DJ, Cheek, HB, Effron, MB and Topol, EJ (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83942-3 |
1998 Conference Publication Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORTBrener, SJ, Ellis, SG, Burchenal, JEB, Katz, S, Effron, MB and Topol, EJ (1998). Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84709-2 |
1998 Conference Publication Synergy of abciximab and ticlopidine in patients undergoing intracoronary stentingKleiman, NS, Graziadei, N, Lance, E, Maresh, K, Taylor, J, Higginbotham, J, Edwards, A, Effron, MB, Mascelli, MA and Jordan, RE (1998). Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84740-7 |
1998 Conference Publication Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)Tcheng, JE, Kereiakes, DJ, George, BS, Braden, G, Langrall, MA, Zelinger, D, Jordan, R and Effron, MB (1998). Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3). NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83944-7 |
1998 Conference Publication Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trialBarr, LA, Brener, SJ, Jones, AA, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84737-7 |
1997 Conference Publication Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER resultsEllis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC. |